PCRX Pacira BioSciences Inc

Price (delayed)

$61.29

Market cap

$2.72B

P/E Ratio

15.25

Dividend/share

N/A

EPS

$4.02

Enterprise value

$3.17B

Highlights
The equity has surged by 77% year-on-year and by 6% since the previous quarter
Pacira BioSciences's gross profit has increased by 23% YoY and by 15% QoQ
The company's quick ratio fell by 40% YoY but it rose by 13% QoQ
Pacira BioSciences's debt has increased by 39% YoY

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
44.45M
Market cap
$2.72B
Enterprise value
$3.17B
Valuations
Price to earnings (P/E)
15.25
Price to book (P/B)
3.93
Price to sales (P/S)
5.38
EV/EBIT
37.1
EV/EBITDA
30.1
EV/Sales
6.3
Earnings
Revenue
$503.08M
EBIT
$85.4M
EBITDA
$105.25M
Free cash flow
$82.87M
Per share
EPS
$4.02
Free cash flow per share
$1.88
Book value per share
$15.61
Revenue per share
$11.4
TBVPS
$25.68
Balance sheet
Total assets
$1.33B
Total liabilities
$638.67M
Debt
$549.27M
Equity
$687.17M
Working capital
$563.89M
Liquidity
Debt to equity
0.8
Current ratio
3.47
Quick ratio
3.13
Net debt/EBITDA
4.21
Margins
EBITDA margin
20.9%
Gross margin
73.8%
Net margin
34.6%
Operating margin
18%
Efficiency
Return on assets
13.6%
Return on equity
27.4%
Return on invested capital
6.4%
Return on capital employed
7.8%
Return on sales
17%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.68%
1 week
2.01%
1 month
3.39%
1 year
9.25%
YTD
2.42%
QTD
1.01%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$503.08M
Gross profit
$371.19M
Operating income
$90.68M
Net income
$174.08M
Gross margin
73.8%
Net margin
34.6%
The company's operating income has surged by 86% QoQ
PCRX's operating margin has soared by 64% QoQ
Pacira BioSciences's gross profit has increased by 23% YoY and by 15% QoQ
The revenue has grown by 23% YoY and by 14% from the previous quarter

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
15.25
P/B
3.93
P/S
5.38
EV/EBIT
37.1
EV/EBITDA
30.1
EV/Sales
6.3
Pacira BioSciences's EPS has increased by 18% QoQ
PCRX's P/E is 18% below its last 4 quarters average of 18.4
The equity has surged by 77% year-on-year and by 6% since the previous quarter
PCRX's P/B is 27% below its 5-year quarterly average of 5.3 and 10% below its last 4 quarters average of 4.3
The revenue has grown by 23% YoY and by 14% from the previous quarter
The price to sales (P/S) is 13% lower than the last 4 quarters average of 6.1

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has soared by 52% from the previous quarter
Pacira BioSciences's return on sales has increased by 48% QoQ
Pacira BioSciences's ROA has increased by 7% from the previous quarter
PCRX's ROE is up by 4.2% since the previous quarter

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 108% greater than the total liabilities
The total assets has surged by 53% year-on-year and by 3% since the previous quarter
The current ratio has contracted by 46% YoY but it has grown by 12% from the previous quarter
Pacira BioSciences's debt is 20% less than its equity
The equity has surged by 77% year-on-year and by 6% since the previous quarter
Pacira BioSciences's debt has increased by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.